Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, USA.
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
Nat Med. 2017 Jun 6;23(6):1-10. doi: 10.1038/nm.4341.
Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis of their site of origin. This Perspective focuses on advances in our understanding of the tumorigenesis and treatment of poorly differentiated neuroendocrine tumors. Recent evidence from sequencing indicates that, although neuroendocrine tumors can arise de novo, they can also develop as a result of lineage plasticity in response to pressure from targeted therapies. We discuss the shared genomic alterations of these tumors independently of their site of origin, and we explore potential therapeutic strategies on the basis of recent biological findings.
神经内分泌（NE）癌是一组多样化的肿瘤，通常根据其起源部位进行诊断和治疗。本观点侧重于我们对低分化神经内分泌肿瘤的肿瘤发生和治疗的理解进展。来自测序的最新证据表明，尽管神经内分泌肿瘤可以从头发生，但它们也可能由于靶向治疗的压力而发生谱系可塑性而发展。我们讨论了这些肿瘤的共享基因组改变，而不考虑其起源部位，并根据最近的生物学发现探索潜在的治疗策略。
